U.S. Infrastructure Stock News

NYSE:CRL
NYSE:CRLLife Sciences

Charles River Laboratories International (CRL) Cut 2026 Guidance, Is The Stock Still 11% Undervalued?

Charles River Laboratories International (CRL) cut its 2026 earnings guidance after reporting a second quarter net loss and slightly lower revenue. The company also continued its share repurchase program during the same period. See our latest analysis for Charles River Laboratories International. Despite the cut to 2026 earnings guidance and the recent quarterly net loss, Charles River Laboratories International’s share price has risen strongly over recent months, with a 30-day share price...
NYSE:BILL
NYSE:BILLSoftware

BILL Stock And 2 Digital Payments Picks Retail Investors May Want To Watch

AI is putting a fresh spotlight on who really profits from personal data, with proposals for $15,000 annual payments to families and talk of a $300b data market and trillion dollar AI IPOs. That debate could reshape how digital payments and benefits infrastructure businesses earn, tax and regulate revenue streams. This article looks at three US stocks exposed to that story and why their future cash flows may matter to your portfolio. The stocks highlighted below are just a sample, and the...
NasdaqGS:PRVA
NasdaqGS:PRVAHealthcare

Should Stronger 2026 Guidance and New Board Expertise Require Action From Privia Health Group (PRVA) Investors?

Privia Health Group, Inc. recently reported second-quarter 2026 results showing higher sales of US$632.63 million and improved profitability, and raised its full-year 2026 GAAP revenue outlook to the high end of its prior US$2.35 billion to US$2.45 billion range. The company also appointed experienced healthcare executive and physician Opella Ernest, M.D. to its Board and Compliance Committee, adding deep payer, clinical, and regulatory expertise that could be important as Privia scales its...
NYSE:ECL
NYSE:ECLChemicals

Raised 2026 Guidance and 89-Year Dividend Streak Could Be A Game Changer For Ecolab (ECL)

Ecolab’s board recently declared a regular quarterly cash dividend of US$0.73 per common share, payable on October 15, 2026, to shareholders of record on September 15, 2026, extending a cash dividend track record that now spans 89 consecutive years. This announcement comes as Ecolab highlights faster growth in its High-Tech, Digital and Life Sciences businesses and raises its 2026 adjusted earnings guidance, underscoring management’s focus on pricing, productivity and share gains even as...
NasdaqGS:DGII
NasdaqGS:DGIICommunications

Digi International (DGII) Earnings And Guidance Raise Fresh Questions About Valuation

Digi International (DGII) drew fresh investor attention after reporting third quarter fiscal 2026 results on 5 August, alongside updated guidance for the fourth quarter and full year revenue. See our latest analysis for Digi International. The earnings release and higher full year revenue guidance arrived after a strong run in Digi International’s stock, with a 30-day share price return of 26.78% and an 87.77% share price return year to date. Over the longer haul, total shareholder return of...
NasdaqGM:XENE
NasdaqGM:XENEBiotechs

Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors?

Xenon Pharmaceuticals Inc. recently reported second-quarter 2026 results, with net loss rising to US$110.74 million and basic loss per share from continuing operations at US$1.11, alongside a six‑month net loss of US$213.04 million and basic loss per share of US$2.28. The widening losses compared with the same periods in 2025 give investors fresh insight into how Xenon is funding its ion-channel neurology pipeline ahead of key clinical and commercial milestones. We will now examine how...
NYSEAM:NHC
NYSEAM:NHCHealthcare

Why National HealthCare (NHC) Is Up 8.1% After Strong Q2 Earnings And Dividend Confirmation

National HealthCare Corporation recently reported past second-quarter 2026 results showing revenue of US$408.03 million and net income of US$40.32 million, alongside strong year-to-date earnings growth versus the prior year period. The company also confirmed it will pay a quarterly cash dividend of US$0.67 per common share to shareholders of record on September 30, 2026, reinforcing its focus on returning cash to investors. We’ll now look at how National HealthCare’s strong earnings growth...
NYSE:ZTO
NYSE:ZTOLogistics

How Stronger Earnings And Buybacks At ZTO Express (Cayman) (ZTO) Have Changed Its Investment Story

ZTO Express (Cayman) Inc. has reported past half‑year 2026 results showing CNY 27,832.26 million in sales and CNY 5,169.22 million in net income, alongside completing a US$138 million buyback of 6,161,216 shares representing 0.8% of its share count. The sharp uplift in both basic and diluted earnings per share from continuing operations highlights how recent operational performance and capital returns are reshaping the company’s financial profile. We’ll now examine how this earnings...
NasdaqGS:FIVE
NasdaqGS:FIVESpecialty Retail

Five Below (FIVE), What Is Behind The Fresh Attention?

Recent store openings and product launches are back in focus for Five Below (FIVE) after new locations in Sioux Falls and Poughkeepsie, alongside a fresh fall room decor range targeting value focused shoppers. See our latest analysis for Five Below. Recent openings like Sioux Falls and Poughkeepsie, along with the new fall room decor line, have coincided with stronger momentum for Five Below, with a 30 day share price return of 17.71% and a 1 year total shareholder return of 68.58%. If these...
NasdaqGS:RPRX
NasdaqGS:RPRXPharmaceuticals

How Investors Are Reacting To Royalty Pharma (RPRX) Buying Rusfertide Royalties From Zealand Pharma

In August 2026, Royalty Pharma plc agreed to provide US$100 million in funding to Zealand Pharma A/S in return for Zealand’s economic interests in rusfertide (PTG-300), including a 1% royalty on potential future global net sales and associated milestone payments, with payments split between closing and the first anniversary. This deal gives Royalty Pharma exposure to a potential first-in-class therapy for polycythemia vera while leaving Zealand Pharma with a smaller upside royalty on very...
NYSE:HSY
NYSE:HSYFood

Hershey (HSY) Expands Halloween Range As A Pricey Valuation Debate Builds

Hershey (HSY) is rolling out its largest Halloween portfolio to date, with more than 20 new products across chocolate, fruity candy and salty snacks, aimed at capturing broader seasonal snacking demand. See our latest analysis for Hershey. Against the backdrop of this expanded Halloween push, Hershey’s 1 month share price return of 7.02% contrasts with a 3 month share price decline of 3.87%. The 1 year total shareholder return of 4.54% sits alongside a 3 year total shareholder return decline...
NYSE:JPM
NYSE:JPMBanks

Does JPMorgan’s Upscale Chicago Flagship Reveal a Deeper Shift in Its Fee Model Strategy (JPM)?

In August 2026, JPMorgan Chase opened an 11,765 square foot two-story flagship at 830 N. Michigan Avenue in Chicago, combining a modern Chase branch with the city’s first co-located J.P. Morgan Financial Center offering everyday banking, lending, and personalized wealth services for affluent clients. This flagship, launched alongside an acceleration in branch openings and renovations nationwide, underlines JPMorgan’s push to blend physical presence with higher-touch advisory services as it...
NasdaqGS:EVCM
NasdaqGS:EVCMSoftware

Will CEO Transition and Lower-End 2026 Guidance Change EverCommerce's (EVCM) Vertical SaaS Narrative?

EverCommerce Inc. reported second-quarter 2026 results showing year-over-year increases in revenue to US$152.02 million and net income to US$9.72 million, while also issuing third-quarter revenue guidance of US$151.5 million to US$154.5 million and indicating full-year 2026 revenue is likely to land near the lower end of its US$612 million to US$632 million range. The company also completed a leadership transition, with founder Eric Remer stepping down as CEO and Chairman and long-time...
NYSE:AS
NYSE:ASLuxury

Should Amer Sports’ Upgraded 2026 Outlook Require Action From Amer Sports (AS) Investors?

In the past few days, Amer Sports reported stronger-than-expected second-quarter results, with revenue rising 32% across all segments and operating margins improving, prompting the company to lift its full-year 2026 adjusted EPS, revenue growth, and adjusted operating margin guidance. This upgraded outlook highlights how Amer Sports’ multi-brand, multi-region model is currently converting broad-based demand into both faster growth and higher profitability expectations. Next, we’ll explore...
NYSE:YETI
NYSE:YETILeisure

Is YETI (YETI) Turning Steady 2026 Guidance Into a Stronger Long‑Term Brand Moat?

In August 2026, YETI Holdings, Inc. reported second-quarter sales of US$483.87 million and net income of US$71.32 million, both higher than a year earlier, and confirmed its full-year 2026 sales growth outlook of 7% to 8%. The combination of stronger earnings, higher earnings per share, and reaffirmed sales guidance has reinforced analyst confidence in YETI’s earnings estimates and overall outlook. With YETI maintaining its 7% to 8% sales growth guidance, we’ll explore how this reinforces or...
NasdaqGS:QFIN
NasdaqGS:QFINConsumer Finance

Qfin Holdings (QFIN), What Is Drawing Fresh Attention Now?

Why Qfin Holdings Stock Is Back On Investors’ Radar Qfin Holdings (NasdaqGS:QFIN) is drawing attention after a difficult year in which the share price declined 56.6%. Yet recent checks suggest the stock still screens as cheap on several valuation metrics. See our latest analysis for Qfin Holdings. Qfin Holdings' recent trading tells a mixed story for momentum. The latest 1-day share price return was 1%, while the 90-day share price return is down 3.98% and the 1-year total shareholder return...
NYSE:GPI
NYSE:GPISpecialty Retail

Group 1 Automotive (GPI) Adds A Director And Affirms Dividend, Is The Stock Too Cheap?

Group 1 Automotive (GPI) drew investor attention after its board appointed former Ulta Beauty CEO David C. Kimbell as a director and audit committee member, and also affirmed a quarterly cash dividend of $0.55 per share. See our latest analysis for Group 1 Automotive. Despite the board refresh and dividend affirmation, Group 1 Automotive’s recent share price performance has been weak, with the stock down 23.32% on a 30 day share price return and 36.32% year to date, while the 5 year total...
NYSE:BR
NYSE:BRProfessional Services

Is Broadridge Financial Solutions (BR) Undervalued On Its Payward Partnership And 2026 Guidance?

Broadridge Financial Solutions (BR) is back in focus after its 2026 guidance and update call on 13 August 2026, following a recent Payward partnership that links its governance platform to tokenized xStocks. See our latest analysis for Broadridge Financial Solutions. Broadridge Financial Solutions has seen momentum pick up recently, with a 30 day share price return of 13.31% and a 90 day share price return of 13.85%. This comes even though the year to date share price return is down 22.96%...
NasdaqGS:ORLY
NasdaqGS:ORLYSpecialty Retail

Is O'Reilly's US$1.6 Billion Debt Raise Quietly Rebalancing Its Funding Strategy and Risk Profile (ORLY)?

In August 2026, O'Reilly Automotive issued and sold US$700,000,000 of 4.800% Senior Notes due 2029, US$500,000,000 of 5.050% Senior Notes due 2031, and US$400,000,000 of 5.550% Senior Notes due 2037, all as senior unsecured obligations under its existing indenture with U.S. Bank Trust Company. This multi-tranche offering, featuring callable senior unsecured notes that sit alongside O'Reilly's existing bond stack, gives the company fresh long-term capital and added flexibility to adjust its...
NYSE:DCH
NYSE:DCHAuto Components

Dauch (DCH) Faces A Valuation Test After Earnings And Guidance

Dauch earnings and guidance set the stage ahead of investor conference Dauch (DCH) heads into its J.P. Morgan Automotive Conference appearance on August 12 following second quarter results that paired higher sales with much lower net income and a full year outlook that still points to a loss. See our latest analysis for Dauch. Dauch's share price has been choppy around the latest earnings and guidance, with a 1 day share price return of down 4.56% and a 7 day share price return of down 5.81%...
NYSE:CMG
NYSE:CMGHospitality

Chipotle (CMG) Stock Trades At A Premium As Shares Fell 23%

Chipotle Mexican Grill stock has fallen 22.9% over the past year, yet the Discounted Cash Flow (DCF) intrinsic value estimate suggests the shares may still be trading at a premium of about 22% to that model. With market multiples looking roughly in line, investors are left with mixed signals on whether the recent weakness has truly reset the valuation. Over the past 12 months the share price has declined 22.9%, which can make the current level look more attractive at first glance even if the...
NasdaqCM:CELH
NasdaqCM:CELHBeverage

Celsius Stock And Two Cross Border Beverage Names Worth A Closer Look

Trade headlines between the US and Canada suddenly matter more for your portfolio. A short pause in new tariffs and talk of a broader deal has put cross border beverage stocks in a different spotlight, as access to consumers on both sides of the border can quickly change. This article walks through three stocks exposed to the news and explains why some investors are watching them so closely right now. The three stocks below are only a first look at this idea, and the full screen surfaced 32...
NasdaqGS:PAGP
NasdaqGS:PAGPOil and Gas

Plains GP Holdings (PAGP) Could Be 9% Overvalued Following Strong Q2 Earnings

Plains GP Holdings (PAGP) released its second quarter 2026 earnings on August 7, reporting higher sales of US$17,693 million and net income of US$389 million compared with the prior year period. See our latest analysis for Plains GP Holdings. The latest earnings release comes after a strong period for Plains GP Holdings, with a 35.5% year to date share price return and a 50.62% total shareholder return over the past year. This suggests momentum has been building as investors reassess both...
NasdaqGS:ARQT
NasdaqGS:ARQTBiotechs

Arcutis Biotherapeutics (ARQT) Could Be 28% Undervalued As Profit And Guidance Improve

Why Arcutis Biotherapeutics Stock Is Back In Focus Arcutis Biotherapeutics (ARQT) is drawing attention after reporting second quarter revenue of $129.86 million, a shift to net income of $15.01 million, and higher full year net product sales guidance. See our latest analysis for Arcutis Biotherapeutics. At a share price of $26.54, Arcutis Biotherapeutics has a 1 day share price return of 3.63%, a 90 day share price return of 29.65%, and a 1 year total shareholder return of 68.29%. These...